drugset / Trial / NCT00005865

Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00005865 ↗

Phase 2 Completed GlaxoSmithKline
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. It is not yet known whether giving vinorelbine by mouth or infusion is more effective in treating non- small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of vinorelbine given by mouth or as an infusion in treating patients who have stage IIIB or stage IV non-small cell lung cancer.

Timeline

Start
2000-04
Primary completion
—
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinorelbine Small molecule 30 mg/m2 Oral
Subject Vinorelbine Small molecule 70 mg/m2 Oral

Indications